JP2004510752A5 - - Google Patents

Download PDF

Info

Publication number
JP2004510752A5
JP2004510752A5 JP2002532304A JP2002532304A JP2004510752A5 JP 2004510752 A5 JP2004510752 A5 JP 2004510752A5 JP 2002532304 A JP2002532304 A JP 2002532304A JP 2002532304 A JP2002532304 A JP 2002532304A JP 2004510752 A5 JP2004510752 A5 JP 2004510752A5
Authority
JP
Japan
Prior art keywords
cells
antibody
monoclonal antibody
fragment
malignant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002532304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510752A (ja
JP4202127B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/030963 external-priority patent/WO2002028481A2/en
Publication of JP2004510752A publication Critical patent/JP2004510752A/ja
Publication of JP2004510752A5 publication Critical patent/JP2004510752A5/ja
Application granted granted Critical
Publication of JP4202127B2 publication Critical patent/JP4202127B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002532304A 2000-10-02 2001-10-02 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 Expired - Fee Related JP4202127B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23755600P 2000-10-02 2000-10-02
PCT/US2001/030963 WO2002028481A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007305086A Division JP2008074870A (ja) 2000-10-02 2007-11-26 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2008220544A Division JP4838831B2 (ja) 2000-10-02 2008-08-28 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法

Publications (3)

Publication Number Publication Date
JP2004510752A JP2004510752A (ja) 2004-04-08
JP2004510752A5 true JP2004510752A5 (enExample) 2005-12-22
JP4202127B2 JP4202127B2 (ja) 2008-12-24

Family

ID=22894238

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2002532486A Expired - Lifetime JP4271440B2 (ja) 2000-10-02 2001-10-02 ヒト抗ｃｄ４０抗体
JP2002532304A Expired - Fee Related JP4202127B2 (ja) 2000-10-02 2001-10-02 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2007299859A Pending JP2008156339A (ja) 2000-10-02 2007-11-19 ヒト抗ｃｄ４０抗体
JP2007305086A Pending JP2008074870A (ja) 2000-10-02 2007-11-26 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2008220544A Expired - Fee Related JP4838831B2 (ja) 2000-10-02 2008-08-28 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2009143746A Pending JP2009201523A (ja) 2000-10-02 2009-06-16 ヒト抗ｃｄ４０抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002532486A Expired - Lifetime JP4271440B2 (ja) 2000-10-02 2001-10-02 ヒト抗ｃｄ４０抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2007299859A Pending JP2008156339A (ja) 2000-10-02 2007-11-19 ヒト抗ｃｄ４０抗体
JP2007305086A Pending JP2008074870A (ja) 2000-10-02 2007-11-26 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2008220544A Expired - Fee Related JP4838831B2 (ja) 2000-10-02 2008-08-28 アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2009143746A Pending JP2009201523A (ja) 2000-10-02 2009-06-16 ヒト抗ｃｄ４０抗体

Country Status (10)

Country Link
US (5) US7288252B2 (enExample)
EP (3) EP1717251B1 (enExample)
JP (6) JP4271440B2 (enExample)
AT (3) ATE541860T1 (enExample)
AU (4) AU2001296507A1 (enExample)
CA (2) CA2424749A1 (enExample)
DE (2) DE60119945T2 (enExample)
ES (1) ES2357051T3 (enExample)
PT (1) PT1326896E (enExample)
WO (4) WO2002028905A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2544364A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
ES2346978T3 (es) * 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
SI1680141T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
JP4746552B2 (ja) * 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006235695B2 (en) 2005-04-09 2011-10-13 Fusion Antibodies Limited Cathepsin S antibody
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
JP5208730B2 (ja) * 2005-05-18 2013-06-12 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
JP2009517339A (ja) * 2005-11-01 2009-04-30 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP2589654A1 (en) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CN101970003A (zh) * 2007-11-09 2011-02-09 诺华有限公司 抗cd40抗体的应用
EP2245065A1 (en) 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
EP2406288B1 (en) 2009-03-10 2016-12-14 Baylor Research Institute Antigen presenting cell targeted vaccines
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
TW201300418A (zh) 2011-03-25 2013-01-01 Baylor Res Inst 用於抗ｃ型肝炎病毒免疫之組合物及方法
US9475879B2 (en) * 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
TR201904882T4 (tr) * 2011-11-17 2019-05-21 Gundram Jung Tıbbi kullanım için bispesifik antikorlar.
JP2016011258A (ja) * 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
JP6475631B2 (ja) 2012-11-19 2019-02-27 バリオファルム・アクチェンゲゼルシャフト Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
HUE054075T2 (hu) 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
HUE056769T2 (hu) 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanizált anti-CD40 antitestek és felhasználásuk
BR112018006360A2 (pt) * 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
PL3468997T3 (pl) 2016-06-08 2024-12-16 Xencor, Inc. Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
UA128304C2 (uk) 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11525005B2 (en) 2017-06-01 2022-12-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
CN108503708B (zh) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
BR112021009835A2 (pt) 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
MX2021006360A (es) 2018-11-30 2021-08-11 Jiangsu Hengrui Medicine Co Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
EP3917960A1 (en) * 2019-02-01 2021-12-08 LAVA Therapeutics N.V. Novel cd40-binding antibodies
NL2022494B1 (en) * 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
EP4305066A1 (en) 2021-03-09 2024-01-17 Genmab A/S Multispecific binding agents against cd40 and cd137 in therapy
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
GB2623267A (en) 2021-05-07 2024-04-10 Redkik Oy Risk probability assessment for cargo shipment operations and methods of use thereof
EP4365200A4 (en) * 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND MEDICAL USE THEREOF
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4393937A4 (en) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd STEROID COMPOUND AND CONJUGATE OF THIS ONE
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US4355023A (en) * 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
DE3773893D1 (de) * 1987-01-17 1991-11-21 Asta Pharma Ag Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994001457A1 (en) 1992-07-07 1994-01-20 Fish Eleanor N Interferon receptor binding peptides
DE69334064T2 (de) * 1992-07-09 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Antagonistische monoklonale Antikörper gegen menschliches CD40
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
KR960704576A (ko) 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002028905A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies

Similar Documents

Publication Publication Date Title
JP2004517611A5 (enExample)
Williams et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.
JP2007513073A5 (enExample)
JP2021526022A5 (enExample)
JP2007512243A5 (enExample)
WO2005044855A3 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
JP2008529497A5 (enExample)
JP2005506035A5 (enExample)
US20110020332A1 (en) Prevention of tumors with monoclonal antibodies against neu
JP2006528626A5 (enExample)
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
JP2014501729A5 (enExample)
JP2023526774A5 (enExample)
RU2009103533A (ru) Способы получения поликлональных антител, антисыворотка, содержащая поликлональные антитела, и способы иммунизации
RU2014122189A (ru) Способы снижения частоты и тяжести острых приступов астмы
JP2008514730A5 (enExample)
JP2007526908A5 (enExample)
CA2370814A1 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
JP2005505256A5 (enExample)
RU2020133229A (ru) Антитела к klk5 и способы применения
JP2021510523A5 (enExample)
JP2023510844A5 (enExample)
JP2019535797A5 (enExample)